OpGen, Inc. – NASDAQ:OPGN

OpGen stock price today

$4.7
+4.06
+637.25%
Financial Health
0
1
2
3
4
5
6
7
8
9

OpGen stock price monthly change

-80.06%
month

OpGen stock price quarterly change

-80.06%
quarter

OpGen stock price yearly change

+44.31%
year

OpGen key metrics

Market Cap
7.45M
Enterprise value
5.38M
P/E
-0.08
EV/Sales
1.33
EV/EBITDA
-0.12
Price/Sales
0.70
Price/Book
0.37
PEG ratio
N/A
EPS
-14.46
Revenue
2.67M
EBITDA
-11.61M
Income
-26.54M
Revenue Q/Q
-81.59%
Revenue Y/Y
-12.38%
Profit margin
-1234.53%
Oper. margin
-1129.63%
Gross margin
-9.01%
EBIT margin
-1129.63%
EBITDA margin
-434.43%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

OpGen stock price history

OpGen stock forecast

OpGen financial statements

OpGen, Inc. (NASDAQ:OPGN): Profit margin
Jun 2023 736.13K -5.82M -791.61%
Sep 2023 699.02K -4.06M -581.23%
Dec 2023 1.06M -17.04M -1593.1%
Mar 2024 168.14K 386.03K 229.58%
OpGen, Inc. (NASDAQ:OPGN): Debt to assets
Jun 2023 22434962 15.57M 69.42%
Sep 2023 18134882 15.45M 85.24%
Dec 2023 1882274 13.44M 714.23%
Mar 2024 2970380 13.68M 460.63%
OpGen, Inc. (NASDAQ:OPGN): Cash Flow
Jun 2023 -4.75M -367.31K 1.50M
Sep 2023 -2.92M -101.73K 27.53K
Dec 2023 -1.67M -914 2.09M
Mar 2024 -1.08M 0 199.72K

OpGen alternative data

OpGen, Inc. (NASDAQ:OPGN): Employee count
Aug 2023 85
Sep 2023 85
Oct 2023 85
Nov 2023 85
Dec 2023 85
Jan 2024 85
Feb 2024 85
Mar 2024 85
Apr 2024 85
May 2024 85
Jun 2024 85
Jul 2024 85

OpGen other data

100.00% +95.51%
of OPGN is owned by hedge funds
164.59K +57.48K
shares is hold by hedge funds

OpGen, Inc. (NASDAQ:OPGN): Insider trades (number of shares)
Period Buy Sel
Apr 2024 350000 0
Jul 2024 0 550000
Aug 2024 7645603 2663961
Transaction Date Insider Security Shares Price per share Total value Source
Purchase
AEI CAPITAL LTD 10 percent owner
Common Stock 514,138 $999,998 $514,136,971,724
Purchase
AEI CAPITAL LTD 10 percent owner
Common Stock 564,971 $999,999 $564,970,435,029
Sale
AEI CAPITAL LTD 10 percent owner
Series E Convertible Preferred Stock 263,961 $2.84 $749,649
Purchase
AEI CAPITAL LTD 10 percent owner
Common Stock 3,600,000 $2,724,490 $9,808,164,000,000
Purchase
AEI CAPITAL LTD 10 percent owner
Common Stock 566,494 $428,724 $242,869,573,656
Purchase
AEI CAPITAL LTD 10 percent owner
Common Stock 600,000 $454,082 $272,449,200,000
Sale
AEI CAPITAL LTD 10 percent owner
Common Stock 600,000 $454,082 $272,449,200,000
Purchase
AEI CAPITAL LTD 10 percent owner
Common Stock 1,800,000 $913,265 $1,643,877,000,000
Sale
AEI CAPITAL LTD 10 percent owner
Common Stock 1,800,000 $913,265 $1,643,877,000,000
Sale
LAZAR DAVID E. director, 10 percent owner, off..
Series E Convertible Preferred Stock 550,000 N/A N/A
Patent
Grant
Filling date: 6 Aug 2018 Issue date: 29 Dec 2020
Application
Filling date: 11 Nov 2019 Issue date: 10 Sep 2020
Grant
Filling date: 27 May 2015 Issue date: 12 Nov 2019
Wednesday, 21 August 2024
investorplace.com
Wednesday, 5 June 2024
investorplace.com
Friday, 24 May 2024
globenewswire.com
Thursday, 16 May 2024
globenewswire.com
Monday, 29 April 2024
globenewswire.com
Tuesday, 23 April 2024
globenewswire.com
Monday, 25 March 2024
globenewswire.com
Friday, 29 September 2023
InvestorPlace
Thursday, 6 July 2023
Zacks Investment Research
Wednesday, 21 June 2023
Zacks Investment Research
Monday, 5 June 2023
Zacks Investment Research
Thursday, 18 May 2023
Zacks Investment Research
Monday, 15 May 2023
Seeking Alpha
Tuesday, 18 April 2023
Zacks Investment Research
Wednesday, 29 March 2023
Seeking Alpha
Thursday, 26 January 2023
PennyStocks
Wednesday, 14 December 2022
PennyStocks
Tuesday, 13 December 2022
InvestorPlace
InvestorPlace
Thursday, 10 November 2022
Seeking Alpha
Thursday, 11 August 2022
Seeking Alpha
Tuesday, 31 May 2022
PennyStocks
Thursday, 12 May 2022
Seeking Alpha
Zacks Investment Research
Tuesday, 29 March 2022
Zacks Investment Research
Seeking Alpha
Tuesday, 18 January 2022
GlobeNewsWire
Friday, 19 November 2021
PennyStocks
Thursday, 11 November 2021
Seeking Alpha
Monday, 18 October 2021
GlobeNewsWire
  • What's the price of OpGen stock today?

    One share of OpGen stock can currently be purchased for approximately $4.7.

  • When is OpGen's next earnings date?

    Unfortunately, OpGen's (OPGN) next earnings date is currently unknown.

  • Does OpGen pay dividends?

    No, OpGen does not pay dividends.

  • How much money does OpGen make?

    OpGen has a market capitalization of 7.45M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 31.11% to 3.42M US dollars.

  • What is OpGen's stock symbol?

    OpGen, Inc. is traded on the NASDAQ under the ticker symbol "OPGN".

  • What is OpGen's primary industry?

    Company operates in the Healthcare sector and Medical - Diagnostics & Research industry.

  • How do i buy shares of OpGen?

    Shares of OpGen can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are OpGen's key executives?

    OpGen's management team includes the following people:

    • Dr. Oliver Schacht Ph.D. Chief Executive Officer, Pres & Director(age: 54, pay: $565,870)
    • Mr. Johannes Bacher Chief Operating Officer(age: 56, pay: $325,000)
  • How many employees does OpGen have?

    As Jul 2024, OpGen employs 85 workers.

  • When OpGen went public?

    OpGen, Inc. is publicly traded company for more then 10 years since IPO on 5 May 2015.

  • What is OpGen's official website?

    The official website for OpGen is opgen.com.

  • Where are OpGen's headquarters?

    OpGen is headquartered at 9717 Key West Avenue, Rockville, MD.

  • How can i contact OpGen?

    OpGen's mailing address is 9717 Key West Avenue, Rockville, MD and company can be reached via phone at +240 8131260.

OpGen company profile:

OpGen, Inc.

opgen.com
Exchange:

NASDAQ

Full time employees:

85

Industry:

Medical - Diagnostics & Research

Sector:

Healthcare

OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILĂšM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.

9717 Key West Avenue
Rockville, MD 20850

CIK: 0001293818
ISIN: US68373L4068
CUSIP: 68373L307